Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 11;78(16):1635–1654. doi: 10.1016/j.jacc.2021.08.021

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the American College of Cardiology Foundation. Published by Elsevier.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Central Illustration — Summary of Ongoing Trials of Lipid-Modulating Agents in Coronavirus Disease-2019

Statins are the most frequently studied lipid-modulating agents in randomized controlled trials of patients with coronavirus disease 2019 (COVID-19). Omega-3 fatty acid preparations are the only studied lipid-modulating agents in the prevention of COVID-19. Niacin is the only lipid-modulating agent being studied for post-acute COVID-19. Additional details are provided in Figures 3, 4, and 5.